Issues with the current drugs for Mycobacterium tuberculosis cure and potential of cell envelope proteins for new drug discovery.
| Title: | Issues with the current drugs for Mycobacterium tuberculosis cure and potential of cell envelope proteins for new drug discovery. |
|---|---|
| Authors: | Mahajan PS; Division of Molecular Biology, ICMR-National AIDS Research Institute, Pune, 411026, India.; Girigosavi P; Division of Molecular Biology, ICMR-National AIDS Research Institute, Pune, 411026, India.; Chauware V; Division of Molecular Biology, ICMR-National AIDS Research Institute, Pune, 411026, India.; Mokashi ND; Postgraduate Institute, Yashwantrao Chavan Memorial Hospital, Pune, 411018, India.; Nema V; Division of Molecular Biology, ICMR-National AIDS Research Institute, Pune, 411026, India. Electronic address: vnema@nariindia.org. |
| Source: | The Indian journal of tuberculosis [Indian J Tuberc] 2023 Jul; Vol. 70 (3), pp. 286-296. Date of Electronic Publication: 2023 Apr 01. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Elsevier Country of Publication: India NLM ID: 0373027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0019-5707 (Print) Linking ISSN: 00195707 NLM ISO Abbreviation: Indian J Tuberc Subsets: MEDLINE |
| Imprint Name(s): | Publication: Jan. 2015- : New Delhi : Elsevier; Original Publication: New Delhi, Tuberculosis Assn. of India. |
| MeSH Terms: | Mycobacterium tuberculosis*/genetics; Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Bacterial Proteins/genetics ; Humans ; Drug Discovery |
| Abstract: | Mycobacterium tuberculosis has been the smartest pathogen ever and a challenge to drug development. Its replicative machinery is unique, so targeting the same for killing the pathogen remains a challenge. Our body typically throws out the drugs before they see the bacterium multiply. The pathogen has also learned how to remove drugs from its internal chambers and not allow them to reach their targets. Another strategy for Mtb is the mutation of the targets to reject drug binding and bypass the drug's inhibitory actions. In this review, we tried to explore possible targets on the outer side of the bacterial cell. We have also explored if those targets are promising enough and if there are drugs or inhibitors available. We also discuss the essential proteins and why they remain to be a good target. We concluded that the cell envelope has got a few proteins that can be targeted in isolation or maybe along with other machinery while making the outer environment more conducive for penetration of current drugs or newly proposed drugs.; (Copyright © 2023 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.) |
| Competing Interests: | Conflicts of interest The authors have none to declare. |
| Contributed Indexing: | Keywords: Cell envelope; Inhibitor; Mycobacterium tuberculosis; New drugs; Target site |
| Substance Nomenclature: | 0 (Antitubercular Agents); 0 (Bacterial Proteins) |
| Entry Date(s): | Date Created: 20230810 Date Completed: 20230814 Latest Revision: 20230814 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.ijtb.2023.03.015 |
| PMID: | 37562902 |
| Database: | MEDLINE |
Journal Article; Review